125 related articles for article (PubMed ID: 24464356)
1. Intraperitoneal paclitaxel induces regression of peritoneal metastasis partly by destruction of peripheral microvessels.
Kitayama J; Emoto S; Yamaguchi H; Ishigami H; Watanabe T
Cancer Chemother Pharmacol; 2014 Mar; 73(3):605-12. PubMed ID: 24464356
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice.
Ohashi N; Kodera Y; Nakanishi H; Yokoyama H; Fujiwara M; Koike M; Hibi K; Nakao A; Tatematsu M
Int J Oncol; 2005 Sep; 27(3):637-44. PubMed ID: 16077911
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer.
Soma D; Kitayama J; Konno T; Ishihara K; Yamada J; Kamei T; Ishigami H; Kaisaki S; Nagawa H
Cancer Sci; 2009 Oct; 100(10):1979-85. PubMed ID: 19604244
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination.
Emoto S; Yamaguchi H; Kishikawa J; Yamashita H; Ishigami H; Kitayama J
Cancer Sci; 2012 Jul; 103(7):1304-10. PubMed ID: 22429777
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal administration of a small interfering RNA targeting nuclear factor-kappa B with paclitaxel successfully prolongs the survival of xenograft model mice with peritoneal metastasis of gastric cancer.
Inoue M; Matsumoto S; Saito H; Tsujitani S; Ikeguchi M
Int J Cancer; 2008 Dec; 123(11):2696-701. PubMed ID: 18798274
[TBL] [Abstract][Full Text] [Related]
7. Thermosensitive hydrogel system assembled by PTX-loaded copolymer nanoparticles for sustained intraperitoneal chemotherapy of peritoneal carcinomatosis.
Xu S; Fan H; Yin L; Zhang J; Dong A; Deng L; Tang H
Eur J Pharm Biopharm; 2016 Jul; 104():251-9. PubMed ID: 27185379
[TBL] [Abstract][Full Text] [Related]
8. Exosomal miR-493 suppresses MAD2L1 and induces chemoresistance to intraperitoneal paclitaxel therapy in gastric cancer patients with peritoneal metastasis.
Makinoya M; Miyatani K; Matsumi Y; Sakano Y; Shimizu S; Shishido Y; Hanaki T; Kihara K; Matsunaga T; Yamamoto M; Tokuyasu N; Takano S; Sakamoto T; Hasegawa T; Saito H; Nakayama Y; Osaki M; Okada F; Fujiwara Y
Sci Rep; 2024 May; 14(1):10075. PubMed ID: 38698201
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice.
Yagi Y; Fushida S; Harada S; Tsukada T; Kinoshita J; Oyama K; Fujita H; Ninomiya I; Fujimura T; Kayahara M; Kinuya S; Yashiro M; Hirakawa K; Ohta T
Cancer Chemother Pharmacol; 2010 Sep; 66(4):745-53. PubMed ID: 20033809
[TBL] [Abstract][Full Text] [Related]
10. Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) in peritoneal metastatic nodules.
Kamei T; Kitayama J; Yamaguchi H; Soma D; Emoto S; Konno T; Ishihara K; Ishigami H; Kaisaki S; Nagawa H
Cancer Sci; 2011 Jan; 102(1):200-5. PubMed ID: 20942868
[TBL] [Abstract][Full Text] [Related]
11. [Intraoperative and postoperative intra-peritoneal administration of peptide PIII inhibits peritoneal metastasis of gastric cancer].
Bai FH; Yang L; Ji Q; Zhang YQ; Liu ZX; Wang ZZ; Yan L; Wang JB; Jin HF; Li TT
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(46):3260-3. PubMed ID: 17313805
[TBL] [Abstract][Full Text] [Related]
12. Intra-peritoneal administration of paclitaxel with non-animal stabilized hyaluronic acid as a vehicle--a new strategy against peritoneal dissemination of gastric cancer.
Yamada J; Kitayama J; Tsuno NH; Yamashita H; Miyato H; Soma D; Otani K; Kamei T; Ishigami H; Hidemura A; Kaisaki S; Takahashi K; Nagawa H
Cancer Lett; 2008 Dec; 272(2):307-15. PubMed ID: 18768251
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of a paclitaxel-loaded nanofibrillated bacterial cellulose (PTX/NFBC) formulation in a peritoneally disseminated gastric cancer xenograft model.
Akagi S; Ando H; Fujita K; Shimizu T; Ishima Y; Tajima K; Matsushima T; Kusano T; Ishida T
Int J Biol Macromol; 2021 Mar; 174():494-501. PubMed ID: 33545180
[TBL] [Abstract][Full Text] [Related]
14. Intravenous paclitaxel against metastasis of human gastric tumors of diffuse type.
Tuan TF; Tsai ML; Yeh KC; Huang HC; Chung CT; Huang CL; Han CH; Chen CP; Wang MH; Shen CC; Lai YK; Lee WS; Hwang LL; Chen CT
Cancer Chemother Pharmacol; 2010 Sep; 66(4):773-83. PubMed ID: 20044750
[TBL] [Abstract][Full Text] [Related]
15. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis.
Ishigami H; Kitayama J; Kaisaki S; Yamaguchi H; Yamashita H; Emoto S; Nagawa H
Oncology; 2010; 79(3-4):269-72. PubMed ID: 21372602
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis.
Yamaguchi H; Kitayama J; Ishigami H; Emoto S; Yamashita H; Watanabe T
Cancer; 2013 Sep; 119(18):3354-8. PubMed ID: 23798046
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer.
De Clercq K; Xie F; De Wever O; Descamps B; Hoorens A; Vermeulen A; Ceelen W; Vervaet C
Sci Rep; 2019 Oct; 9(1):14881. PubMed ID: 31619730
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer.
Shah DK; Veith J; Bernacki RJ; Balthasar JP
Cancer Chemother Pharmacol; 2011 Oct; 68(4):951-8. PubMed ID: 21305289
[TBL] [Abstract][Full Text] [Related]
20. Dexamethasone inhibits the effect of paclitaxel on human ovarian carcinoma xenografts in nude mice.
Hou WJ; Guan JH; Dong Q; Han YH; Zhang R
Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2902-8. PubMed ID: 24254559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
